SHOUTI
ShouTi specializes in the discovery and development of drugs against a type of targets called GPCR. The company develops drugs focused on novel small molecules for multiple unmet medical needs. ShouTi is currently operating in Stealth mode.
SHOUTI
Social Links:
Industry:
Biotechnology Health Care Medical Pharmaceutical Product Research
Founded:
2016-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.shoutipharma.com
Total Employee:
11+
Status:
Active
Total Funding:
207 M USD
Technology used in webpage:
SPF Euro Microsoft Exchange Online Office 365 Mail GoDaddy DNS Cloudflare Hosting Microsoft DMARC DKIM
Similar Organizations
ArriVent Biopharma
ArriVent develops pharmaceutical products to cure presently untreatable cancer.
GigaGen
GigaGen specialized in the early discovery and development of recombinant biotherapeutic medicines.
Hendrick Resources
Hendrick Resources specializes in the discovery and development of precious and base metals.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Productboard
Productboard is a product management system that helps organizations get the right products to market faster.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Piper Heartland Healthcare Capital
Piper Heartland Healthcare Capital investment in Series B - ShouTi
Deep Track Capital
Deep Track Capital investment in Series B - ShouTi
Surveyor Capital
Surveyor Capital investment in Series B - ShouTi
Woodline Partners
Woodline Partners investment in Series B - ShouTi
TF Capital
TF Capital investment in Series B - ShouTi
Lilly Asia Ventures
Lilly Asia Ventures investment in Series B - ShouTi
Casdin Capital
Casdin Capital investment in Series B - ShouTi
Eight Roads Ventures
Eight Roads Ventures investment in Series B - ShouTi
Cormorant Asset Management
Cormorant Asset Management investment in Series B - ShouTi
TCG Crossover
TCG Crossover investment in Series B - ShouTi
Key Employee Changes
| Date | New article |
|---|---|
| 2021-12-21 | ShouTi Appoints Ding Ding, Ph.D., as Chief Financial Officer |
Official Site Inspections
http://www.shoutipharma.com Semrush global rank: 1.97 M Semrush visits lastest month: 10.92 K
Unable to get host informations!!!
More informations about "ShouTi"
ShouTi Secures $100 Million Series B Financing to …
Oct 20, 2021 ShouTi Secures $100M Series B Financing to Accelerate Development of Medicines Fueled by Advanced Computational, Structure …See details»
Home | Structure Therapeutics
Aug 6, 2025 Structure is a clinical-stage biopharmaceutical company leveraging structure-based drug design to develop more accessible oral small molecule therapeutics for the treatment of …See details»
@ShouTiPharma | X
The latest posts from @ShouTiPharmaSee details»
ShouTi ’s Competitors, Revenue, Number of Employees, Funding
ShouTi ’s Profile, Revenue and Employees. ShouTi is a California-based biopharmaceutical company that develops and commercializes small molecule drugs for the treatment of chronic …See details»
ShouTi Inc - Company Profile and News - Bloomberg Markets
Company profile page for ShouTi Inc including stock price, company news, executives, board members, and contact informationSee details»
ShouTi Inc. Company Information - Funding, Investors, and More
Get information on funding, investors, industries, and more for ShouTi Inc.. See ShouTi Inc. company profile and funding data.See details»
Structure Therapeutics - Crunchbase Company Profile …
Structure Therapeutics specializes in the discovery and development of drugs against a type of targets called GPCR.See details»
ShouTi Introduces Basecamp Bio as a Wholly Owned Subsidiary
Feb 17, 2022 “With all of these breakthrough technologies under one roof, and access to the Shanghai biotech contract research organization ecosystem as a resource, Basecamp Bio has …See details»
Receptos founder returns with ShouTi and $100M for …
Oct 26, 2021 First it was Syrrx. Then, Receptos. Now, Raymond Stevens, Ph.D., has gathered $100 million to fuel ShouTi, a biotech he founded in 2017 to …See details»
ShouTi - CoBee Company Profile & Funding Rounds
ShouTi is a California-based biopharmaceutical company that develops and commercializes small molecule drugs for the treatment of chronic diseases.See details»
Shouti: Contact Details and Business Profile - RocketReach
Shouti is a Drug Discovery, and Biotechnology company_reader located in South San Francisco, California with 39 employees. Find top employees, contact details and business statistics at …See details»
ShouTi Secures $100 Million Series B Financing to Accelerate ...
Oct 20, 2021 San Francisco and Shanghai – Oct. 20, 2021 – ShouTi Inc., a clinical-stage biopharmaceutical company creating life-changing medicines for patients using advanced …See details»
Shoutipharma / ShouTi
. Check shoutipharma valuation, traffic estimations and owner info. Full analysis about shoutipharma.com.See details»
ShouTi Introduces Basecamp Bio as a Wholly Owned Subsidiary to …
ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today introduced Basecamp Bio, a wholly owned …See details»
ShouTi Raises $100M in Series B to “Replace Biologic Injections …
Oct 21, 2021 San Francisco and Shanghai-based ShouTi wants to replace biological drugs with small molecules that can mimic their function. The clinical-stage biopharma has recently …See details»
ShouTi’s Rationally Designed Small Molecules are ... - BioSpace
May 17, 2022 ShouTi believes many targets addressed by biologic and peptide therapeutics can be reached by innovative, rationally-designed, best-in-class small molecules that don’t need …See details»
ShouTi secures $100M to hit biologic and peptide targets with …
Oct 20, 2021 ShouTi Pharmaceuticals, a startup that brings computational techniques to drug discovery, has raised $100 million in Series B financing. The clinical-stage biotech designs …See details»
ShouTi Secures $100 Million Series B Financing to Accelerate ...
Oct 20, 2021 SAN FRANCISCO & SHANGHAI– ShouTi Inc., a clinical-stage biopharmaceutical company creating life-changing medicines for patients using advanced computational and …See details»
Structure Therapeutics, formerly known as ShoutTi, files for $100M …
Jan 13, 2023 Chinese-American drug developer Structure Therapeutics (GPCR), formerly known as ShoutTi, has filed to raise $100M through a US initial public offering.See details»
ShouTi Appoints Ding Ding, Ph.D., as Chief Financial Officer
Dec 21, 2021 For more information, visit www.shoutipharma.com and follow the company on Twitter @ ShouTiPharma and LinkedIn.See details»